{"url_path":"/sec/ird/8-k/2026-09-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1228627/0001140361-26-036277-index.html","accession_number":"0001140361-26-036277","cik":"0001228627","ticker":"IRD","issuer_name":"Opus Genetics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1228627/0001140361-26-036277-index.html","primary_entity_key":"0001228627","primary_entity_name":"Opus Genetics, Inc."},"word_count":284,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn September 11, 2026, Opus Genetics, Inc. (the “Company”) issued a revised version of the Company’s data presentation, which\nwas initially used in connection with its investor conference on September 9, 2026, announcing clinical data from Cohort 1 of the Company’s ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases. The\noriginal data presentation was furnished by the Company on a Current Report on Form 8-K on September 9, 2026.\n\n \n\nThe revised version of the data presentation, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, corrects\nan immaterial error in the translation of logMAR visual acuity into ETDRS letters, which impacted the depiction of mean best-corrected visual acuity from baseline through 3 months in Cohort 1 on Slide 15. The correct three month change from\nbaseline for each participant is as follows:  101-101 had a 12 letter improvement in the treated eye and a 4 letter improvement in fellow eye, 101-104 had a 1 letter improvement in the treated eye and a 7 letter loss in the fellow eye, 102-101\nhad a 10 letter loss in the treated eye and an 8 letter loss in the fellow eye, 102-102 had a 2 letter gain in the treated eye and a 5 letter loss in the fellow eye, and 101-106 had a 6 letter gain in the treated eye and a 2 letter gain in the\nfellow eye. In addition to the update on Slide 15, high-resolution images of the microperimetry grids for baseline and 3 months were added to the Appendix of the revised presentation for each participant. Individual loci data is available for the\nthree participants in these images."}